Imipenem/cilastatin treatment of acute infections in AIDS/ARC patients

J Chemother. 1990 Aug;2(4):247-51. doi: 10.1080/1120009x.1990.11739025.

Abstract

We studied the clinical efficacy and safety of imipenem, a broad spectrum beta-lactam antibiotic, in acute bacterial infections in 21 patients with AIDS or AIDS-related complex (ARC). Imipenem/cilastatin was administered as a 30-min intravenous infusion using a dose of 500 mg/8 h. Bacterial pathogens were isolated before treatment in 80% of cases; 87.5% of all strains were susceptible to imipenem in vitro. Treatment resulted in rapid control of the infections in 80% of patients. Clinical and laboratory adverse reactions probably related to imipenem treatment were noted in 8 patients.

Publication types

  • Clinical Trial

MeSH terms

  • AIDS-Related Complex / complications*
  • Acquired Immunodeficiency Syndrome / complications*
  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acute Disease
  • Adult
  • Cilastatin / administration & dosage
  • Cilastatin / therapeutic use*
  • Cilastatin, Imipenem Drug Combination
  • Drug Combinations
  • Female
  • Humans
  • Imipenem / administration & dosage
  • Imipenem / therapeutic use*
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Respiratory Tract Infections / complications
  • Respiratory Tract Infections / drug therapy*
  • Risk Factors
  • Sepsis / complications
  • Sepsis / drug therapy*

Substances

  • Drug Combinations
  • Cilastatin
  • Imipenem
  • Cilastatin, Imipenem Drug Combination